U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H15ClO4
Molecular Weight 318.752
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOFIBRIC ACID

SMILES

CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O

InChI

InChIKey=MQOBSOSZFYZQOK-UHFFFAOYSA-N
InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)

HIDE SMILES / InChI

Molecular Formula C17H15ClO4
Molecular Weight 318.752
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4500.0 nM [EC50]
1000.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FIBRICOR

Approved Use

FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (> 500 mg/dL); to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Launch Date

1.25020799E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.37 μg/mL
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
12 μg/mL
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
124 μg × h/mL
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
162.96 μg × h/mL
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Other AEs: Constipation, Diarrhea...
Other AEs:
Constipation (3.3%)
Diarrhea (3.9%)
Dyspepsia (3.7%)
Nausea (4.3%)
Fatigue (2%)
Pain (3.5%)
Nasopharyngitis (3.5%)
Sinusitis (3.3%)
Upper respiratory tract infection (5.3%)
ALT increased (1.2%)
Arthralgia (3.9%)
Back pain (6.3%)
Muscle spasms (1.6%)
Myalgia (3.3%)
Pain in extremity (4.5%)
Dizziness (4.1%)
Headache (12.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
ALT increased 1.2%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Muscle spasms 1.6%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Headache 12.7%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Fatigue 2%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Constipation 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Myalgia 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Sinusitis 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Nasopharyngitis 3.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Pain 3.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Dyspepsia 3.7%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Arthralgia 3.9%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Diarrhea 3.9%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Dizziness 4.1%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Nausea 4.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Pain in extremity 4.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Upper respiratory tract infection 5.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
Back pain 6.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
n = 490
Health Status: unhealthy
Age Group: adult
Population Size: 490
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
yes [IC50 2.2 uM]
yes [IC50 20 uM]
yes [IC50 282 uM]
yes [IC50 741 uM]
weak (co-administration study)
Comment: IC50 value from pre-incubation study; Coadministration with efavirenz (CYP2B6 substrate) resulted in AUC decrease of efavirenz by 12%
Page: 11.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
no
no
no
no
no
no
no
no
no
PubMed

PubMed

TitleDatePubMed
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
2001 Jun
PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.
2002 Jan 25
Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid.
2002 May 1
Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells.
2003 Aug 15
Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists.
2003 Jun
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.
2004 Jan 15
Fenofibrate and fenofibric acid analysis by capillary electrophoresis.
2004 Jun
A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
2004 Sep
Optimal lipid modification: the rationale for combination therapy.
2005
Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms.
2005 Oct 3
Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
2005 Sep 15
Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.
2005 Sep 15
The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.
2006
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.
2006 Dec
Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.
2006 Jun
Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
2006 Mar
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.
2007 May
Cryptochrome and Period Proteins Are Regulated by the CLOCK/BMAL1 Gene: Crosstalk between the PPARs/RXRalpha-Regulated and CLOCK/BMAL1-Regulated Systems.
2008
PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.
2008 Aug 15
A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
2008 May
An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection.
2008 May 2
Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
2008 May-Jun
Treatment of hyperlipidaemia with fenofibrate and related fibrates.
2008 Oct
Advances in the medical treatment of diabetic retinopathy.
2009 Aug
Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.
2009 Dec
Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine.
2009 Jun
IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
2009 Jun
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
2009 May
Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.
2009 Nov
Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study.
2009 Sep
Substance Class Chemical
Created
by admin
on Fri Dec 16 20:29:48 UTC 2022
Edited
by admin
on Fri Dec 16 20:29:48 UTC 2022
Record UNII
BGF9MN2HU1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENOFIBRIC ACID
ORANGE BOOK   VANDF   WHO-DD  
Common Name English
PROCETOFENIC ACID
Common Name English
FIBRICOR
Brand Name English
FENOFIBRIC ACID [ORANGE BOOK]
Common Name English
FENOFIBRATE FREE ACID [MI]
Common Name English
FENOFIBRATE RELATED COMPOUND B [USP-RS]
Common Name English
PROPANOIC ACID, 2-(4-(4-CHLOROBENZOYL)PHENOXY)-2-METHYL-
Common Name English
LF-153
Code English
FENOFIBRIC ACID [VANDF]
Common Name English
NSC-281318
Code English
FENOFIBRATE RELATED COMPOUND B
USP-RS  
Common Name English
FENOFIBRIC ACID [USP-RS]
Common Name English
Fenofibric acid [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175596
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
NCI_THESAURUS C98150
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
Code System Code Type Description
RXCUI
24852
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY RxNorm
FDA UNII
BGF9MN2HU1
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
EPA CompTox
DTXSID8041030
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
PUBCHEM
64929
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
EVMPD
SUB34521
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
NSC
281318
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
CAS
42017-89-0
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
WIKIPEDIA
Fenofibric acid
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
RS_ITEM_NUM
1269436
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
CHEBI
83469
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
DAILYMED
BGF9MN2HU1
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
MERCK INDEX
M5279
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
RS_ITEM_NUM
1269618
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
ALTERNATIVE
ChEMBL
CHEMBL981
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
NCI_THESAURUS
C83804
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
MESH
C006012
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
DRUG BANK
DB13873
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
ECHA (EC/EINECS)
255-626-9
Created by admin on Fri Dec 16 20:29:48 UTC 2022 , Edited by admin on Fri Dec 16 20:29:48 UTC 2022
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
MINOR
URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY